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Accepted 11 June 2013; Published online 24 September 2013AbstractObjectives: To investigate whether physicians’ prescribing preferences were valid instrumental variables for the antidepressant pre-
scriptions they issued to their patients.
Study Design and Setting: We investigated whether physicians’ previous prescriptions of (1) tricyclic antidepressants (TCAs) vs. se-
lective serotonin reuptake inhibitors (SSRIs) and (2) paroxetine vs. other SSRIs were valid instruments. We investigated whether the in-
strumental variable assumptions are likely to hold and whether TCAs (vs. SSRIs) were associated with hospital admission for self-harm
or death by suicide using both conventional and instrumental variable regressions. The setting for the study was general practices in the
United Kingdom.
Results: Prior prescriptions were strongly associated with actual prescriptions: physicians who previously prescribed TCAs were 14.9
percentage points (95% confidence interval [CI], 14.4, 15.4) more likely to prescribe TCAs, and those who previously prescribed paroxetine
were 27.7 percentage points (95% CI, 26.7, 28.8) more likely to prescribe paroxetine, to their next patient. Physicians’ previous prescrip-
tions were less strongly associated with patients’ baseline characteristics than actual prescriptions. We found no evidence that the estimated
association of TCAs with self-harm/suicide using instrumental variable regression differed from conventional regression estimates
(P-value 5 0.45).
Conclusion: The main instrumental variable assumptions held, suggesting that physicians’ prescribing preferences are valid instru-
ments for evaluating the short-term effects of antidepressants.
 2013 The Authors. Published by Elsevier Inc.
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Open access under 1. Introduction
In observational research, confounding by indication can
bias estimates of drug treatment effects on outcomes that are
associated with the indications for treatment [1,2]. Standard
statistical approaches to deal with this adjust associations for
observed covariates [3]. However, many confounders are
difficult or impossible to measure [4], and a number of ob-
servational associations have been contradicted by subse-
quent randomized controlled trials [5,6]. This has been
ascribed to unmeasured or residual confounding by indica-
tion. Observational studies can also suffer from reverse cau-
sation and protopathic biases, in which preclinical
symptoms of diseases affect prescribing decisions or the
ability of patients to comply with a treatment regime [7,8].
One approach to address these sources of bias is instrumen-
tal variable analysis [9e16]. This uses naturally occurringCC BY license.
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 Physicians’ prior antidepressant prescribing pat-
terns were strongly associated with their subse-
quent prescriptions.
 Physicians’ prior antidepressant prescriptions were
less strongly associated with the observable base-
line characteristics of patients (potential con-
founders) than the actual prescriptions.
 Multiple prior prescriptions were more strongly as-
sociated with the actual prescription than a single
prior prescription.
 Prior prescriptions can potentially be used to esti-
mate treatment effects using observational data in
the presence of unmeasured confounding by indi-
cation when investigating the short-term effects
of antidepressants.
 There was no evidence that the association of
TCAs vs. SSRIs with self-harm/death by suicide
was affected by residual confounding because the
results from conventional ordinary least squares re-
gression were similar to the instrumental variable
results. However, this may be because of the im-
precision of the instrumental variable results.variation in likelihood of prescription, ‘‘the instrumental
variable’’ or ‘‘instrument,’’ that is associated with the actual
prescription but, unlike the actual prescription, is not asso-
ciated with observed and unobserved confounding factors.
Variation in drug prescribing associated with the instru-
ments can provide unconfounded estimates of causal rela-
tionships between being prescribed a drug and an
outcome, provided a set of assumptions are met (see
Box 1).
Brookhart et al. [17] proposed that physicians’ prefer-
ences for medications could be an instrumental variable
for the actual prescriptions their patients received. In most
observational datasets, it is not possible to directly measure
physicians’ prescribing preferences; therefore, Brookhart
et al. argued that the prescriptions issued by physicians to
their previous patients could be used as a proxy of their
preferences, and hence that prior prescriptions could be
used as a surrogate instrument. Brookhart et al. used this
concept to estimate the effects of cyclooxygenase-2 selec-
tive inhibitors vs. traditional nonselective nonsteroidal
anti-inflammatory drugs (NSAIDs) on upper gastrointesti-
nal complications [17]. They found that physicians’ prior
prescriptions predicted the actual prescriptions received
and that associations of potential confounders with physi-
cians’ prior prescriptions were weaker than with the actual
prescriptions. Furthermore, conventional multivariateregression methods found little difference in rates of upper
gastrointestinal complications by actual prescription,
whereas an instrumental variable analysis, using physi-
cians’ prior prescriptions as a surrogate instrument for ac-
tual prescriptions, found evidence that patients prescribed
cyclooxygenase-2 selective inhibitors had fewer upper gas-
trointestinal complications, in line with randomized con-
trolled trials [18e21]. The methods have been developed
in subsequent studies [15,22e29].
There has previously been concern about whether selec-
tive serotonin reuptake inhibitors (SSRIs), in particular pa-
roxetine, cause suicide-related serious adverse events
[30e33]. In this study, we evaluated physicians’ prescrib-
ing preferences as an instrument for patients’ prescriptions
of tricyclic antidepressants (TCAs) vs. SSRIs and paroxe-
tine vs. SSRIs, using data from the United Kingdom’s Clin-
ical Practice Research Datalink (formerly the General
Practice Research Database). To evaluate the three assump-
tions underpinning instrumental variable analysis, we pres-
ent associations of prior prescriptions (the surrogate
instrument) with actual prescription and compare the
strength of associations of potential confounders with prior
prescriptions to that of the actual prescriptions received. We
also developed the methodology by evaluating the proper-
ties of alternative instruments based on a greater number
of prior prescriptions.2. Methods
The Clinical Practice Research Datalink (www.cprd.
com) is an administrative and clinical database containing
data on over 11 million patients (4.5 million of whom are
currently registered) from over 600 general practices across
Britain [34]. Registered patients are representative of Brit-
ain’s demography in terms of age, sex, and geographical
distribution [35]. Data are validated, audited, quality
checked [36,37], and have been used in over 800 peer-
reviewed articles [36,38e41].
2.1. Study participants
We identified all patients ever registered with a practice
contributing to the Clinical Practice Research Datalink be-
fore June 20, 2011, and whose records indicated that they
had been prescribed an SSRI or a TCA (Appendix at
www.jclinepi.com) while registered with the practice.
We extracted data relating to all the antidepressant pre-
scriptions given to these patients. We excluded prescrip-
tion records if they occurred before the patients were
registered at the practice, were missing a prescription
date, or occurred after the patient’s registration end. We
kept the first prescription issued to each of the remaining
patients. Of these, we excluded (1) patients first prescribed
an antidepressant within 12 months of joining the practice
as these may have been repeat prescriptions for medicines
first prescribed by their previous general practitioner; (2)
Box 1 The assumptions for instrumental variable analysis and how they are met in this study
Assumption
How assumptions are met
True instrument (preference) Surrogate instrument (prior prescription)
[A] The instrumental variable is associated
with the actual prescription.
Physicians’ preferences for particular
antidepressants are associated with the
actual prescription they issue to their
current patient.
A physician’s prescription to their previous
patient is a surrogate or proxy for their
preferences. This surrogate is associated
with the actual prescription they issue to
their next patient.
[B] The instrumental variable does not di-
rectly affect the outcomes.
Physicians’ preferences for particular
antidepressants are unlikely to directly
affect their patients’ outcomes.
A physician’s prescription to their previous
patient is unlikely to directly affect their
next patient’s outcomes.
[C] The instrumental variable is not associ-
ated with the confounding factors.
Physicians’ preferences for particular
antidepressants may not be associated
with potential confounding factors (e.g., an
individual with a history of self-harm)
because patients’ choices of physician are
quasi-random.
A physician’s prescription to their previous
patient may not be associated with their
next patient’s characteristics.
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1995, or after June 30, 2010 (we chose 1995 because this
was the first year of linked Hospital Episodes Statistics
data) [42]; (3) patients issued prescriptions by staff mem-
bers who were not a physician (because of ambiguity re-
garding who had made the prescribing decision); (4)
patients’ prescriptions missing the prescribing physicians’
identifier; (5) patients who were younger than 10 years
when first prescribed an antidepressant because prescrib-
ing in children could be for other indications; (6) patients
missing the year of birth; and (7) patients whose physician
previously prescribed fewer than 10 prescriptions because
they had insufficient prescriptions to accurately determine
preference. For the TCA vs. SSRI comparison, we ex-
cluded patients whose physician had not previously pre-
scribed TCAs or SSRIs. For the paroxetine vs. other
SSRIs comparison, we excluded patients prescribed TCAs
and those whose physician had not previously prescribed
an SSRI. We defined the index date as the date on which
each patient received their first prescription; for the rest of
the article, we refer to this prescription as the ‘‘patient’s
actual prescription.’’2.2. Actual prescription
We compared two sets of medications. First, we com-
pared those first prescribed a TCA with those prescribed
an SSRI. Second, among those prescribed SSRIs as their
first antidepressant, we compared those first prescribed pa-
roxetine with those prescribed other SSRIs.2.3. Instruments
Our proposed instruments are physicians’ preferences
for particular antidepressants [17]. Physicians’ prefer-
ences are an unobserved continuous latent variable. Weused physicians’ choice of antidepressant prescribed to
one or more of their previous patients as a proxy for their
current preferences and hence as a surrogate instrumental
variable for actual prescriptions. Thus, each patient’s phy-
sician was defined as having higher or lower preferences
for TCAs or SSRIs among those first prescribed antide-
pressants and higher or lower preferences for either parox-
etine or other SSRIs among those first prescribed SSRIs.
Our primary surrogate instrument was the physicians’
most recent prior prescription. For the TCAs vs. SSRIs
comparison, we defined the surrogate instrument as equal
to one if the patient’s physician previously prescribed
a TCA and zero if they prescribed a SSRI. For the parox-
etine vs. nonparoxetine SSRI analysis, we defined the sur-
rogate instrument as equal to one if the physician
previously prescribed paroxetine and zero if they pre-
scribed a nonparoxetine SSRI.
The assumptions defining an instrumental variable are
described in Box 1 and illustrated in Fig. 1.
Physicians’ preferences are likely to affect many of their
previous prescriptions, not just their most recent prior pre-
scription. Therefore, we hypothesized that alternative mea-
sures of prior prescriptions may be more strongly
associated with each patient’s actual prescription. In a sec-
ondary analysis, we also investigated whether we could
construct better instruments using multiple prior prescrip-
tions from each physician. Specifically, we investigated
whether two pragmatically defined alternative specifica-
tions of surrogate instruments, using longer prescription
histories for each physician, could increase the strength
of the association of the prior prescriptions with the actual
prescriptions. First, we used a count of the number of TCA
(or paroxetine) prescriptions issued by each physician to
their previous three patients. Second, we defined a set of
indicator variables for each physician’s previous seven pre-
scriptions. We defined these alternative instruments without
Fig. 1. Directed acyclic graph of outcomes Y, prescriptions X, instru-
mental variable the unmeasured physician prescribing preference U*,
surrogate instrument physicians’ prior prescriptions Z, and unmea-
sured confounders U (data from Hernan and Robins [15]).
1389N.M. Davies et al. / Journal of Clinical Epidemiology 66 (2013) 1386e1396first looking at the data as defining instruments because of
the strength of their association with the exposure can lead
to bias [43e45].
2.4. Potential confounding factors
We investigated associations of our surrogate instru-
ments with the following potential confounding factors
(factors associated with both suicide risk and prescribing
decisions [46]): body mass index (BMI), hospitalization
in the prior year, having more than 13 primary care consul-
tations in the prior year, age, having more than five pre-
scriptions in the prior year, gender, ever smoked, prior
diagnosis of depression or self-harm, previous prescription
of hypnotics (British National Formulary chapter 4.1.1) or
antipsychotics (British National Formulary chapter 4.2.1
or 4.2.2), whether the patient had a nonzero Charlson Index
(an index of morbidity) before prescription, and year of first
prescription (to account for prescribing trends) [47]. We ex-
cluded records with a BMI of more than 100 or less than 15
in case they were data errors.
2.5. Tests of the instrumental variable assumptions
We investigated the validity of the first assumption [A],
by testing the strength of association of the prior prescrip-
tions with the actual prescription using a partial F-test
[11,48] from a regression of the actual prescription on prior
prescription adjusted for prescription year, using robust
standard errors clustered by the physician who issued the
prescription [49]. The partial F-statistic tests whether the
instruments are associated with the exposure after condi-
tioning on included covariates (in this case year of first
prescription).
We evaluated whether assumption [C] held by estimat-
ing risk differences of each confounding factor by patients’actual prescriptions and by measures of the prior prescrip-
tions. We estimated these risk differences for patients first
prescribed TCAs vs. those prescribed SSRIs and for those
prescribed paroxetine vs. those prescribed nonparoxetine
SSRIs, using crude and multivariate-adjusted ordinary least
squares regression, with robust standard errors clustered by
physician [49]. We used ordinary least squares rather than
logistic regression to allow comparison of our results with
previous articles [17,23]. Prescription rates for each drug
changed over time so all models control for the year of first
prescription. We also report the Mahalanobis distance,
a summary measure of the total covariate imbalance, for
both prior prescriptions (the instrument) [23,50] and actual
prescriptions. We report the percentage reduction in the
Mahalanobis distance between the actual prescriptions
and the instruments.
We estimated the prevalence difference ratio to assess
whether the bias due to each potential confounding factor
was likely to be larger in a conventional or instrumental
variables analysis [24]:pdr5
EðUjZ51Þ EðUjZ50Þ
EðUjX51Þ EðUjX50Þwhere U indicates the covariate of interest, and Z and X are
the prior and actual prescriptions, respectively. If the prev-
alence difference ratio is greater than the strength of the
surrogate instrument EðXjZ51Þ  EðXjZ50Þ, then the bias
due to the confounder in the instrumental variable results
may be greater than the conventional results. So, if physi-
cians who previously prescribed a TCA prescribed TCAs
to 15 extra patients per 100 and the prevalence difference
ratio is greater than 0.15, then the instrumental variable re-
sults may be more biased than the conventional ordinary
least squares results.
We investigated the associations of the surrogate instru-
ments based on longer treatment histories (count of the pre-
vious three and indicator variables for the seven previous
prescriptions) with the actual prescriptions and the ob-
served covariates. We regressed each covariate on the set
of surrogate instruments and adjusted for year of prescrip-
tion. We used F-tests to assess the joint null hypothesis of
no association of the prior prescriptions with the covariates.
We estimated the strength of associations of each definition
of surrogate instruments and actual prescription. We tested
whether the additional prescriptions explained any addi-
tional variance in the exposure using a Lagrange multiplier
test [51].
We used these instruments to investigate whether pa-
tients prescribed TCAs were more likely to die by suicide
or be admitted to hospital for self-harm compared with
those prescribed SSRIs using linked administrative data
from the Office of National Statistics (for mortality data)
and Hospital Episode Statistics (for admission data). These
outcomes have been previously validated [52]. We only had
linked data for 50% of general practices, so we limited this
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effect estimates between conventional ordinary least
squares regression and instrumental variable regression us-
ing a DurbineWueHausman test [53,54], and compared
these results to a propensity scoreeadjusted analysis. We
derived propensity scores using sampling with replacement
and a tolerance in the difference in the propensity score be-
tween matched patients of 0.01. We included all the cova-
riates listed in Table 1 except BMI because BMI had
missing values. We undertook three sensitivity analyses.
First, we tested whether there was any evidence of a direct
effect of physicians on suicide or self-harm by including
physician fixed effects (using an indicator variable for each
of the 3,042 physicians in the sample). Second, we repeated
the analysis excluding low-dose amitriptyline (i.e., pre-
scriptions!13 mg in one analysis and!70 mg in another)
because such doses may have been prescribed for nonde-
pression diagnoses such as neuropathic pain. Finally, we in-
creased the precision of the results using seven previous
prescriptions.
All analyses were conducted in Stata (version 12.0 Sta-
taCorp, TX), using robust standard errors clustered by phy-
sician; we used the command IVREG2 for the instrumental
variable analyses, XTIVREG2 for the fixed-effects instru-
mental variable analyses, and propensity scores were de-
rived using PSMATCH2 [55e57].3. Results
We identified 897,983 patients prescribed either SSRIs
or TCAs between January 1, 1995, and June 30, 2010.
We dropped 11,248 patients whose physician issued fewerTable 1. Potential confounders by first antidepressant prescribed (TCAs vs.
Variable
Actual prescription P
TCAs (%) SSRIs (%)
N 484,858 401,877
BMI O 25 kg/m2 (N 5 679,755) 57.7 50.7
Hospitalized in prior year 0.4 0.3
More than 13 consultations in prior year 76.8 58.6
Older than 40 at first prescriptions 71.9 50.8
More than five prescriptions in prior year 71.1 48.9
Malea 37.7 39.6
Ever smoked 40.9 56.8
Diagnosed depressed before prescription 43.2 62.0
Prior diagnosis of definite self-harm 5.8 5.8
Prior hypnotic prescriptions 16.5 12.8
Prior antipsychotic prescriptions 2.4 2.0
Prior Charlson Index not zero 42.1 33.4
Percent prescribed before 2004 50.8 45.9
Mahalanobis distance 18.5 16.8
Reduction in Mahalanobis distance
Abbreviations: TCA, tricyclic antidepressant; SSRI, selective serotonin r
All estimates adjusted for year of first prescription. The number of patien
of 11,277 patients whose physicians had previously prescribed at least 10
a One patient missing gender.
b Mean difference.than 10 prescriptions or had not previously issued a pre-
scription. This left 886,735 patients, who attended 6,555
physicians at 612 general practices, for inclusion in the
analysis. Altogether, 484,858 patients were issued a TCA
and 401,877 an SSRI, 45,238 of whom were issued parox-
etine. On average, each physician issued 135 in total, or 21
per year, first-time antidepressant prescriptions. In the
3 months after first prescription, we identified 608 cases
of death by suicide or hospital admission for self-harm,
an incident rate of 0.15 per 100 patients treated, or 600
per 100,000 patient-years.
We found evidence of differences in baseline variables
(potential confounders) between patients prescribed TCAs
and those prescribed SSRIs (Table 1). The only covariate
in which there was no difference was a prior diagnosis of
self-harm. The differences between the actual prescription
groups were considerable: those prescribed TCAs (vs.
SSRIs) were 21.3 percentage points more likely to be more
than 40 years of age, 22.5 percentage points more likely to
have had more than five prescriptions of any type in the
year before the antidepressant was issued, and were 8.8 per-
centage points more likely to have a Charlson index of at
least one. Although we found evidence of differences be-
tween patients depending on their physicians’ previous
prescription (the instrument), these differences were con-
siderably smaller than when comparing what was actually
prescribed: patients whose physician previously prescribed
a TCA were 2.5 percentage points more likely to be more
than 40 years of age, 2.1 percentage points more likely to
have been issued more than five prescriptions in the previ-
ous year, and 1.2 percentage points more likely to have
a Charlson index of at least one. Patients prescribed TCAs
were 5.0 percentage points more likely to be prescribedSSRIs)
hysicians’ prior prescription Risk difference per 100, TCAs vs. SSRIs
TCAs (%) SSRIs (%)
Actual
prescription
Physicians’ prior
prescription
484,692 402,043
55.0 54.1 7.08b 0.92b
0.4 0.4 0.10 0.02
69.2 67.7 18.42 1.50
63.5 61.0 21.28 2.50
62.0 59.9 22.45 2.13
38.8 38.3 1.83 0.46
47.2 49.3 16.11 2.15
50.6 53.1 19.01 2.56
5.9 5.7 0.04 0.16
14.6 15.1 3.78 0.59
2.3 2.2 0.42 0.05
38.7 37.5 8.83 1.18
50.8 45.8 4.95 5.04
17.9 17.6 1.75 0.29
83%
euptake inhibitor; BMI, body mass index.
ts in this table is more than those prescribed SSRIs in Table 2 because
TCAs but prescribed fewer than 10 SSRIs.
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scriptions, therefore prior prescriptions are unlikely to re-
duce confounding by prescription year. The total
imbalance in the covariates, as measured by the Mahalano-
bis distance, was 83% lower for the prior prescription than
the actual prescription.
We found smaller differences between those issued pre-
scriptions for paroxetine vs. those issued other SSRIs
(Table 2): patients prescribed SSRIs were 2.2 percentage
points less likely to have had more than 13 consultations
in the year before the prescription, 4.0 percentage points
more likely to be male, and 5.2 percentage points less likely
to be diagnosed with depression before the index prescrip-
tion. There was little evidence of differences by the prior
type of SSRI prescription for most patient characteristics,
except BMI and gender (patients whose physician previ-
ously prescribed paroxetine were 0.56 percentage points
more likely to have BMI more than 25 and 0.51 percentage
points more likely to be male). However, the type of pre-
scription prescribed changed over time, probably reflecting
concerns about suicide risk associated with paroxetine [58].
Thus, patients whose physician previously prescribed pa-
roxetine were 49.4 percentage points more likely to have
received their prescription before 2004; therefore, we ad-
justed all our results for year of first prescription. The Ma-
halanobis distance was 22% lower for prior prescriptions of
paroxetine vs. other SSRIs than for actual prescriptions.
This difference is considerably smaller than the 83% reduc-
tion seen in the TCAs vs. SSRIs (see above).
We found that physicians’ previous prescriptions were
strongly associated with patients’ actual prescriptionsTable 2. Potential confounders by first antidepressant prescribed (paroxetin
Variable
Actual
prescription
Paroxetine (%) SSRIs (%)
N 44,470 346,130
BMI O 25 kg/m2 (N 5 290,301) 49.1 49.9
Hospitalized in prior year 0.3 0.3
More than 13 consultations in prior year 57.5 59.4
Older than 40 at first prescriptions 50.0 49.7
More than five prescriptions in prior year 47.7 49.4
Malea 42.6 39.2
Ever smoked 56.7 56.4
Diagnosed depressed before prescription 56.7 61.1
Prior diagnosis definite self-harm 6.4 6.2
Prior hypnotic prescriptions 13.0 12.8
Prior antipsychotic prescriptions 2.5 1.9
Prior Charlson Index not zero 32.7 33.8
Percent prescribed before 2004 89.6 40.2
Mahalanobis distance 17.9 16.8
Reduction in Mahalanobis distance
Abbreviations: SSRI, selective serotonin reuptake inhibitors; BMI, body
All statistics adjusted for year of first prescription. Definition of SSRI ex
those prescribed SSRI in Table 1 because of 11,277 patients whose phys
scribed fewer than 10 SSRIs.
b Mean difference.
a One patient missing gender.(Table 3). Physicians who previously prescribed a TCAwere
15 percentage points more likely to prescribe a TCA to their
next patient, and physicians who previously prescribed pa-
roxetine were 28 percentage points more likely to prescribe
paroxetine to their next patient. The partial F-test was 3,663
for TCAs vs. SSRIs and 2,770 for SSRIs vs. paroxetine, sug-
gesting that prior prescriptions are sufficiently strong to use
as surrogate instruments for actual prescriptions.
The prevalence difference ratios (Table 4) suggest that
instrumental variableebased results for TCAs (vs. SSRIs)
have smaller bias (prevalence difference ratio !14.95,
Table 3) than that of the conventional analysis, for all cova-
riates except hospitalization in the prior year, gender, or
a prior diagnosis of self-harm. For these variables, the
strength of the association of confounder with actual pre-
scription was relatively weak, implying that the bias due
to these variables may be relatively small. The prescribing
difference ratios for paroxetine suggest that for only 6 of
the 12 covariates would the instrumental variable results
have smaller bias (prevalence difference ratio smaller than
28% for number of consultations, number of prescriptions,
gender, age at first prescription, a prior diagnosis of depres-
sion, prior prescription of an antipsychotic). This may be
because the strength of the associations of actual prescrip-
tions with the covariates was weaker for SSRIs vs. paroxe-
tine than for TCAs compared with SSRIs.
Including more prior prescriptions in the definition of
the surrogate instrument increased the strength of the joint
association with actual prescription (Appendix at www.
jclinepi.com). For TCAs, the F-test was 3,663 for one prior
prescription compared with 1,971 for the count of thee vs. nonparoxetine SSRIs)
Physicians’ prior
prescription
Risk difference per 100
paroxetine vs. other SSRIs
Paroxetine (%) SSRIs (%)
Actual
prescription
Physicians’
prior prescription
45,238 345,362
50.3 49.9 0.91 0.56
0.4 0.3 0.02 0.10
59.0 59.2 2.23 0.26
49.9 49.8 0.34 0.06
49.1 49.2 1.97 0.15
40.0 39.6 3.99 0.51
56.6 56.4 0.37 0.25
60.4 60.8 5.18 0.45
6.4 6.2 0.26 0.23
12.6 12.8 0.18 0.22
2.0 2.0 0.69 0.01
34.1 33.7 1.31 0.43
89.5 40.1 49.43 49.36
17.7 16.9 1.11 0.87
22%
mass index.
cludes paroxetine. The number of patients in this table is fewer than
icians had previously prescribed at least 10 antidepressants but pre-
Table 3. Association of patients’ actual prescription with physicians’ previous prescription for TCAs vs. SSRIs and paroxetine vs. SSRIs, adjusted for
year of first prescription
Instrument
TCAs vs. SSRIs Paroxetine vs. SSRIs
Risk difference (95% CI) Risk difference (95% confidence interval)
Prior prescription 14.90 (14.42, 15.38) 27.72 (26.69, 28.76)
N 886,735 390,600
Number of physicians (clusters) 6,555 5,144
F-test F(1, 6554) 5 3,663 F(1, 5143) 5 2,770
Partial r2 0.02 0.08
Abbreviations: TCA, tricyclic antidepressant; SSRI, selective serotonin reuptake inhibitor; CI, confidence interval.
All CIs robust for heteroskedasticity and clustered by physician. Risk difference is difference in probability of TCA or paroxetine actually being
prescribed if the physician previously prescribed a TCA or paroxetine (e.g., in row 1, if the physician previously prescribed a TCA, their current
patient is 15% more likely to also be prescribed a TCA than a SSRI).
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for the physicians’ seven previous prescriptions increased
the strength of the association further; the F-test was
1,469, which reduced the standard error to 0.09. In addition
to the variance in exposure explained by a single prior pre-
scription, the six extra prescriptions explained more of the
variance in the exposure (Langrage multiplier
test 5 1,622 | c2 [6]; P ! 0.001). Each of the prior pre-
scriptions, when included individually, was independently
associated with actual prescription. Similarly for paroxe-
tine, the count of the previous prescriptions was more
strongly associated with the actual prescription than a single
prior prescription (Appendix at www.jclinepi.com) (Langr-
age multiplier test 5 925 | c2 [6]; P ! 0.001). Including
extra prescriptions reduced the sample by 49,330 (4.4%)
for the TCAs vs. SSRIs analysis and by 30,864 (7.9%)
for the paroxetine vs. other SSRIs analysis (because the firstTable 4. Prevalence difference ratios for TCAs vs. SSRIs and
paroxetine vs. SSRIs
Variable
Prevalence difference ratio
TCAs vs.
SSRIS (%)
Paroxetine
vs. SSRIs (%)
N 886,735 390,600
BMI O 25 kg/m2 (N 5 290,756) 13.3 61.8
Hospitalized in prior year 19.9 493.1
More than 13 consultations in prior year 8.4 11.8
Older than 40 at first prescriptions 11.8 18.9
More than five prescriptions in prior year 9.7 7.6
Male 28.6 12.9
Ever smoked 13.5 68.0
Diagnosed depressed before prescription 13.4 8.8
Prior diagnosis definite self-harm 292.7 89.2
Prior hypnotic prescriptions 14.6 121.2
Prior antipsychotic prescriptions 12.2 0.9
Prior Charlson Index not zero 14.5 32.9
Abbreviations: TCA, tricyclic antidepressant; SSRI, selective sero-
tonin reuptake inhibitor; BMI, body mass index.
When the prevalence difference ratio is greater than the strength of
the instrument’s association with the actual prescriptions, then the in-
strumental variable results may be more biased than the conventional
results. The strength of the association for the TCAs vs. SSRIs analy-
sis was 15% and for paroxetine vs. SSRIs it was 28%.seven patients seen by each physician have fewer than
seven prior prescriptions to include in the analysis).
There was little evidence that including more prior pre-
scriptions in the definition of the surrogate instrument in-
creased the association with the confounders (Appendix
at www.jclinepi.com). For TCAs vs. SSRIs, both the count
of three prior prescriptions and indicator variables for the
seven prior prescriptions had a smaller F-statistic than the
single prior prescription. However, neither definition using
multiple instruments consistently had the lowest association
with the covariates. For paroxetine vs. SSRIs, the count of
three prior prescriptions was more strongly associated with
the confounders than a single prior prescription (Appendix
at www.jclinepi.com), but there was little evidence that the
seven prior prescriptions were jointly associated with any
of the covariates.
Using conventional ordinary least squares regression, we
found that fewer patients prescribed TCAs had an admis-
sion to hospital for self-harm or died by suicide than those
prescribed SSRIs (risk difference per 100 patients pre-
scribed [RD], 0.11; 95% confidence interval [CI],
0.14, 0.08; Table 5). In contrast, the risk difference cal-
culated using one prior prescription as the instrumental var-
iable was attenuated by approximately 50% toward the null
(RD 5 0.04; 95% CI, 0.21, 0.13), although the CI was
wider (less precise) and we could not reject the null hypoth-
esis of no difference between the conventional and instru-
mental variable analyses (Hausman test: P 5 0.45). The
results based on seven prior prescriptions were more pre-
cise (RD 5 0.10; 95% CI, 0.20, 0.01) but remained
consistent with the conventional analysis. The results using
physician fixed effects were similar to those based on one
prior prescription as the instrument. Excluding low-dose
amitriptyline (either!13 or!70 mg) made no meaningful
differences to the results. The propensity scoreeadjusted
results indicated a similar magnitude of effect but were
more precise than the instrumental variable results.4. Discussion
Physicians’ previous prescriptions of antidepressants
were associated with their patients’ actual prescriptions of
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1393N.M. Davies et al. / Journal of Clinical Epidemiology 66 (2013) 1386e1396antidepressants. This is consistent with the findings of pre-
vious studies of other medications that found that physi-
cians’ previous prescriptions can be used as surrogate
instruments for prescriptions of NSAIDs and antipsychotics
[17,27]. We found that including more prior prescriptions
increased the strength of the association between prior pre-
scriptions and actual prescription. The patients’ actual pre-
scriptions were strongly associated with patients’
characteristics and prescription histories. This suggests that
confounding bias is possible in conventional estimates us-
ing multivariate adjustment or a propensity score. If ob-
served covariates are correlated with the outcome and
exposure, then unobserved (and unmeasured) confounding
variables may also be correlated with outcome and the ex-
posure. In contrast, the prior prescriptions were less
strongly associated with the observed covariates. There
was little evidence that the strength of these associations
with covariates increased when we used a greater number
of prior prescriptions as surrogate instruments. For many
of the covariates, particularly the covariates most strongly
associated with the actual prescriptions such as prior diag-
nosis of depression and number of prior prescriptions, in-
strumental variable estimates using prior prescriptions
may have smaller bias than conventional analysis, as can
be seen in Table 4 [24].
Although the instrumental variable estimate of the effect
of TCAs vs. SSRIs on self-harm and death by suicide was
attenuated by approximately 50% toward the null compared
with the results from conventional regression, the CIs of the
instrumental variable estimates were wide, and there was
little statistical evidence of any difference between the con-
ventional and instrumental variable analysis (Hausman test:
P 5 0.45). This implies that the conventional results may
not suffer from residual or uncontrolled confounding, al-
though our sample size is likely to have been underpowered
to detect differences between the conventional and instru-
mental variable estimates. The propensity score results
were attenuated compared with the conventional regression
results but were consistent with the instrumental variable
results. The instrumental variable results (based on one
prior prescription) suggested that prescribing TCAs (rather
than SSRIs) was unlikely to reduce risk by more than 0.21
or increase risk by more than 0.13 events per 100 patients
treated. This compares with a suicide or self-harm inci-
dence rate of 0.15 per 100 patients treated, suggesting that
prescribing TCAs is unlikely to more than double the risks
of suicide or self-harm compared with SSRIs. The instru-
mental variable results based on seven prior prescriptions
were more precise, suggesting TCAs were unlikely to re-
duce risk by more than 0.20 or increase risk by more than
0.01 per 100 patients treated compared with SSRIs.
Instrumental variable results using prior prescriptions
estimate the effects of being prescribed paroxetine or TCAs
relative to being prescribed other SSRIs. The specific pa-
tients for whom the effects of prescription would be identi-
fied depend on the assumptions used to identify the results.
1394 N.M. Davies et al. / Journal of Clinical Epidemiology 66 (2013) 1386e1396If the results are identified by assuming a monotonic effect
of physicians’ preferences on likelihood of prescription
(e.g., that a patient prescribed paroxetine by a particular
physician would also have been prescribed paroxetine in
a counterfactual situation in which they attended a physician
with higher preferences for paroxetine), the results would
reflect an average effect of prescription in the group of pa-
tients affected by their physicians’ preferences. An alterna-
tive identifying assumption is no effect modification by
values of the instrument. This assumes that the physicians’
previous prescriptions do not change the effect of the med-
ication. If the results are identified by no effect modifica-
tion, then we would identify the effects of prescription on
those prescribed. Both the assumption of no effect modifi-
cation and monotonicity are metaphysical assumptions;
therefore, there is no way to test if they hold [59]. However,
because the instruments do not necessarily estimate an av-
erage treatment effect across the entire population, they
may not be comparable with results from a randomized
controlled trial. The instrumental variable results also
may not reflect the treatment effects in patients who are
never likely to be prescribed one of the drugs, for example,
those with strong contraindications (e.g., paroxetine in
children).
Although we cannot assess the degree of confounding by
unobserved variables, the relative strength of associations
of several observed characteristics, with first, the surrogate
instrument (prior prescriptions) and second, the patient’s
actual prescription, gives an indication of the likely associ-
ations with potential unobserved confounding variables
[59].
Three previous studies have investigated the properties
of different definitions of physicians’ prescribing prefer-
ences. Hennessey et al. [60] found that the physicians’ most
recent prior prescriptions of NSAIDs were more strongly
associated with their patients’ actual prescriptions than old-
er prescriptions. Ionescu-Ittu et al. [61] found that the
instrument most strongly associated with patients’ treat-
ments was the proportion of each hospital’s previous pa-
tients who were treated with rhythm vs. rate control
therapy for atrial fibrillation. Finally, Rassen et al. [23]
found that restricting their analysis to high-volume prac-
tices maximized the strength of their instrument for pre-
scribing antipsychotic medications, and consequently the
precision of their results. We add to these findings in three
ways. First, physicians’ prior prescriptions are potentially
valid surrogate instruments for antidepressants in the
United Kingdom’s Clinical Practice Research Datalink as
they were associated with physicians’ subsequent prescrip-
tions and less associated with potential confounders than
patients’ actual prescriptions. Second, using multiple prior
prescriptions as the instrument increased the precision of
the instrumental variable estimates. Finally, we specified
the assumptions needed to estimate the effects of antide-
pressants on an outcome and described the patients for
whom we could identify the effects of prescription.4.1. Strengths and limitations
Our sample is the largest ever used in an investigation
of physicians’ prescribing preferences and the first study
to investigate alternative definitions of surrogate instru-
ments using multiple prior prescriptions in the Clinical
Practice Research Datalink. The prescribing data are of
high quality and measure prescriptions that the physicians
issued to their patients. This is also the first study to inves-
tigate whether physicians’ preferences are valid instru-
ments for prescriptions of antidepressants. As we used
data from standard clinical care, rather than data collected
specifically to evaluate a particular drug, the results may
be more representative of the effects of prescriptions as
used in the community.
A limitation of our study is that we only have data on
prescriptions issued, not on prescriptions cashed. This
means we cannot identify the effects of treatment, only
the effects of being issued a prescription. Hence, if a med-
ication has poor compliance when used in mainstream
clinical care, then instrumental variable results may be at-
tenuated relative to the results of a randomized controlled
trial with greater compliance. However, this intention-to-
treat parameter may be of more interest to physicians
who have less influence over compliance than they do over
which medication is issued. Therefore, we do not believe
this to be a major limitation. Another limitation was that
we only investigated data from the United Kingdom, so
these findings may not necessarily hold in other settings.
But, our findings are consistent with previous international
studies, which suggests physicians’ prescribing prefer-
ences may be more widely valid. Finally, our results inves-
tigating the validity and utility of physicians’ prescribing
preferences for suicide and self-harm are not necessarily
informative for other outcomes.5. Conclusions
Physicians’ previous prescriptions are potential surro-
gate instruments for patients’ actual prescriptions when in-
vestigating the effects of antidepressants and can address
problems of unmeasured and residual confounding in ob-
servational studies investigating the effects of antidepres-
sants. We found that prior prescriptions of antidepressants
were less associated with observed confounders; hence,
they may be less associated with unobserved confounders
as well. There was more evidence of associations between
covariates and actual prescription in the TCA vs. SSRI
analysis, suggesting that analyses comparing TCAs with
SSRIs may be more likely to suffer from unmeasured or re-
sidual confounding than when comparing paroxetine to
other SSRIs. We demonstrated that including more than
one previous prescription as surrogate instruments for each
physician’s preferences can potentially increase the preci-
sion of instrumental variable results. The most precise
1395N.M. Davies et al. / Journal of Clinical Epidemiology 66 (2013) 1386e1396specification used seven previous prescriptions. Using con-
ventional regression, we found evidence that patients pre-
scribed TCAs were less likely to be admitted to hospital
for self-harm or die by suicide. Our instrumental variable
regressions were less precise and found little evidence of
a large difference in suicide or self-harm between TCAs
and SSRIs. Despite their imprecision, our instrumental vari-
able results based on one prior prescription can exclude
a more than doubling of risk of suicide or self-harm among
those prescribed TCAs vs. SSRIs. Our instrumental vari-
able results based on seven prior prescriptions were precise
enough to exclude an increased risk of suicide or self-harm
among those prescribed TCAs vs. SSRIs and were consis-
tent with the conventional results. The continued develop-
ment of large administrative databases, such as the
Clinical Research Practice Datalink, provides an ideal
source of data for instrumental variable analysis.
Appendix
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2013.06.008.
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